Novo Nordisk CEO Defends Lawsuit Against Eli Lilly Over Weight-Loss Drug Ads

MT Newswires Live08:06

Novo Nordisk CEO Mike Doustdar defended the drugmaker's lawsuit against Eli Lilly over advertising for its weight-loss drugs, saying competition should be fierce but fair, CNBC reported Wednesday.

Novo sued Lilly last month, alleging its advertising misleads consumers about the efficacy of Lilly's Zepbound compared with Novo's Wegovy. Lilly has said it stands firmly behind its advertising, CNBC reported.

Doustdar said Lilly's comparisons rely on an older, lower-dose version of Wegovy and do not reflect Novo's newer 7.2-milligram dose, which was approved by the FDA in March.

Novo said a study of the higher dose showed average weight loss of about 19% over 72 weeks, compared with 20.2% for the maximum tolerated Zepbound dose in Lilly's cited trial, CNBC reported.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment